Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CSL (AU:CSL)
ASX:CSL
Holding AU:CSL?
Track your performance easily
CSL Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$256.15 - AU$313.55
Previous CloseAU$273.72
Volume33.37K
Average Volume (3M)597.24K
Market Cap
AU$132.54B
Enterprise ValueAU$131.35B
Total Cash (Recent Filing)$10.44B
Total Debt (Recent Filing)$9.66B
Price to Earnings (P/E)32.8
Beta0.53
Next Earnings
Feb 11, 2025EPS Estimate
AU$6.69Last Dividend Ex-Date
Sep 09, 2024Dividend Yield1.53%
Share Statistics
EPS (TTM)8.36
Shares OutstandingN/A
10 Day Avg. Volume609,053
30 Day Avg. Volume597,243
Standard Deviation0.05
R-Squared0.18
Alpha0.00188
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)8.50
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$329.39Price Target Upside18.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
CSL News
PremiumCompany Announcements
CSL CEO Adjusts Holdings in Company Securities
PremiumCompany Announcements
CSL Limited Issues New Employee Incentive Securities
PremiumCompany Announcements
CSL Limited Announces Cessation of Securities
PremiumCompany Announcements
CSL Limited Resolutions Passed Amid Shareholder Dissent
PremiumCompany Announcements
CSL Limited Reviews 2024 Performance at Annual Meeting
PremiumCompany Announcements
CSL Limited’s Strategic Issuance of Unquoted Securities
PremiumCompany Announcements
CSL Limited Hosts 2024 R&D Investor Briefing
Options Prices
Currently, No data available
---
Ownership Overview
0.05% Insiders
4.95% Mutual Funds
0.04% Other Institutional Investors
87.67% Public Companies and
Individual Investors
CSL FAQ
What was CSL’s price range in the past 12 months?
CSL lowest share price was AU$256.15 and its highest was AU$313.55 in the past 12 months.
What is CSL’s market cap?
Currently, no data Available
When is CSL’s upcoming earnings report date?
CSL’s upcoming earnings report date is Feb 11, 2025 which is in 81 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Aug 12, 2024. The company reported AU$2.8 earnings per share for the quarter, beating the consensus estimate of AU$2.753 by AU$0.047.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Undervalued.
Does CSL pay dividends?
CSL pays a Semiannually dividend of AU$2.19 which represents an annual dividend yield of 1.53%. See more information on CSL dividends here
What is CSL’s EPS estimate?
CSL’s EPS estimate is AU$6.69.
How many shares outstanding does CSL have?
CSL has 484,206,570 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of AU$2.8 in its last earnings report, beating expectations of AU$2.753. Following the earnings report the stock price went down -4.581%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in AU:CSL
---
CSL Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$329.39 (18.84% Upside)
AU$329.39 (18.84% Upside)
Blogger Sentiment
Bullish
AU:CSL Sentiment 66%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.61%
12-Months-Change
Fundamentals
Return on Equity
15.94%
Trailing 12-Months
Asset Growth
4.93%
Trailing 12-Months
Company Description
CSL
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.
---
CSL Company Deck
---
CSL Earnings Call
Q4 2024
0:00 / 0:00
---
CSL Stock 12 Month Forecast
Average Price Target
AU$329.39
▲(18.84% Upside)
Technical Analysis
Best Analysts Covering CSL
1 Year
1 Year Success Rate
8/20 ratings generated profit
1 Year Average Return
-0.53%
reiterated a buy rating 3 months ago
Copying Andrew Paine's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -0.53% per trade.
---